Ignite Creation Date:
2025-12-17 @ 3:57 PM
Ignite Modification Date:
2025-12-23 @ 10:08 PM
Study NCT ID:
NCT00757835
Status:
COMPLETED
Last Update Posted:
2020-12-17
First Post:
2008-09-19
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG
Sponsor:
Aristotle University Of Thessaloniki
Organization:
Study Overview
Official Title:
24-hour IOP Control With the Travoprost/Timolol Fixed Combination Compared With the Latanoprost/Timolol Fixed Combination, When Both Are Dosed in the Evening in Patients With Exfoliative Glaucoma
Status:
COMPLETED
Status Verified Date:
2020-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A crossover, randomized, single-masked study which compares the short-term (3 months) 24-hour IOP control and safety of travoprost/timolol fixed combination given once in the evening, versus that of latanoprost/timolol fixed combination given once in the evening in patients with exfoliative glaucoma. The primary objective of this trial is to compare the quality of 24-hour IOP control after 3 months of chronic therapy with these two medications.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: